Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival

Journal of Neuro-Oncology

Volumn 97, Issue 1, 2010, Pages 33-40

  McBride, Sean M ^a   Perez, Daniel A ^b   Polley, Mei Yin ^c   Vandenberg, Scott R ^c   Smith, Justin S ^c   Zheng, Shichun ^c   Lamborn, Kathleen R ^c   Wiencke, John K ^c   Chang, Susan M ^c   Prados, Michael D ^c   Berger, Mitchel S ^c   Stokoe, David ^d   Haas Kogan, Daphne A ^b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GENENTECH INC   (United States)

Author keywords

Low grade glioma; MTOR; PRAS40; PTEN; Rapamycin

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; S6 KINASE; SERINE;

ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL TIME;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; SERINE; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; SULFITES; YOUNG ADULT;

EID: 77949265515     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0004-4     Document Type: Article

References (16)

1. M Agulnik WP Mason 2006 The changing management of low-grade astrocytomas and oligodendrogliomas Hematol Oncol Clin North Am 20 1249 1266 10.1016/j.hoc.2006.09.003 17113461 (Pubitemid 44739213)
2. BK Rasheed RE McLendon JE Herndon, et al. 1994 Alterations of the TP53 gene in human gliomas Cancer Res 54 1324 1330 1:CAS:528:DyaK2cXitFCjtr8%3D 8118823
3. J Reifenberger G Reifenberger L Liu, et al. 1994 Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p Am J Pathol 145 1175 1190 1:CAS:528:DyaK2MXit1Wksb8%3D 7977648
4. M Varela SM Ranuncolo A Morand, et al. 2004 EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas J Surg Oncol 86 34 40 10.1002/jso.20036 1:CAS:528: DC%2BD2cXjslertrk%3D 15048678 (Pubitemid 38490098)
5. F Maiuri ML Del Basso De Caro G Iaconetta C Peca M Esposito E de Divitiis 2006 Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas Zentralbl Neurochir 67 204 209 10.1055/s-2006-942138 1:STN:280:DC%2BD28jgtFKltg%3D%3D 17106834 (Pubitemid 44951682)
6. M Mollemann M Wolter J Felsberg VP Collins G Reifenberger 2005 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors Int J Cancer 113 379 385 10.1002/ijc.20575 15455350 (Pubitemid 40038704)
7. AG Contreras O Dormond M Edelbauer, et al. 2008 mTOR-understanding the clinical effects Transplant Proc 40 S9 S12 10.1016/j.transproceed.2008.10.011 1:CAS:528:DC%2BD1cXhsFajtL7O 19100913
8. EK Geissler 2008 The impact of mTOR inhibitors on the development of malignancy Transplant Proc 40 S32 S35 10.1016/j.transproceed.2008.10.017 1:CAS:528:DC%2BD1cXhsFajt7fP 19100904
9. MA Bjornsti PJ Houghton 2004 The TOR pathway: a target for cancer therapy Nat Rev Cancer 4 335 348 10.1038/nrc1362 1:CAS:528:DC%2BD2cXjsFSlu7Y%3D 15122205
10. AS Strimpakos EM Karapanagiotou MW Saif KN Syrigos 2009 The role of mTOR in the management of solid tumors: an overview Cancer Treat Rev 35 148 159 10.1016/j.ctrv.2008.09.006 1:CAS:528:DC%2BD1MXivVWiu7w%3D 19013721
11. G Xu W Zhang P Bertram XF Zheng H McLeod 2004 Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors Int J Oncol 24 893 900 1:CAS:528:DC%2BD2cXjtlaju7c%3D 15010827
12. MS Neshat IK Mellinghoff C Tran, et al. 2001 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR Proc Natl Acad Sci USA 98 10314 10319 10.1073/pnas.171076798 1:CAS:528:DC%2BD3MXmvFWiurk%3D 11504908 (Pubitemid 32803017)
13. TF Cloughesy K Yoshimoto P Nghiemphu, et al. 2008 Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma PLoS Med 5 e8 10.1371/journal.pmed.0050008 18215105 (Pubitemid 351198268)
14. S Volarevic G Thomas 2001 Role of S6 phosphorylation and S6 kinase in cell growth Prog Nucleic Acid Res Mol Biol 65 101 127 10.1016/S0079-6603(00) 65003-1 1:CAS:528:DC%2BD3MXnt1Wgs7g%3D 11008486
15. L Wang TE Harris JC Lawrence 2008 Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation J Biol Chem 283 15619 15627 10.1074/jbc.M800723200 1:CAS:528:DC%2BD1cXmsFektbs%3D 18372248
16. JE Dancey 2006 MTOR and related pathways Cancer Biol Ther 5 9 1065 1073 1:CAS:528:DC%2BD2sXktlejsQ%3D%3D 16969122